Patrick Hwu: Moffitt Cancer Center is thrilled to collaborate with AstraZeneca

Patrick Hwu shared on LinkedIn:

“Moffitt Cancer Center is thrilled to collaborate with AstraZeneca. By combining our clinical expertise with AstraZeneca’s innovative pipeline of investigational cell therapies, global footprint and leadership in oncology, we aim to bring potential new cell therapies to patients faster and more efficiently.”

Read further.
Source: Patrick Hwu/LinkedIn

Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.

Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.